The angiogenic growth factor and biomarker midkine is a tumor-shared antigen

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 418-423

  Kerzerho, Jerome ^a   Adotevi, Olivier ^b,c   Castelli, Florence A ^a   Dosset, Magalie ^b,c   Bernardeau, Karine ^d   Szely, Natacha ^a   Lang, Francois ^d   Tartour, Eric ^b,c   Maillere, Bernard ^a  

^a Institute Frederic Joliot   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MIDKINE; TUMOR ANTIGEN; ANGIOGENIC PROTEIN; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MDK PROTEIN, HUMAN; NERVE GROWTH FACTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR IMMUNITY; ADULT; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

ADULT; ANGIOGENIC PROTEINS; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NERVE GROWTH FACTORS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77956219747     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901014     Document Type: Article

References (51)

1. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54: 187-207.
2. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
3. Jäger, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jäger, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71: 142-147. (Pubitemid 27252981)
4. Riker, A., J. Cormier, M. Panelli, U. Kammula, E. Wang, A. Abati, P. Fetsch, K. H. Lee, S. Steinberg, S. Rosenberg, and F. Marincola. 1999. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120. (Pubitemid 29382769)
5. Brasseur, F., M. Marchand, R. Vanwijck, M. Hérin, B. Lethé, P. Chomez, and T. Boon. 1992. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int. J. Cancer 52: 839-841.
6. Serrano, A., B. Lethé, J. M. Delroisse, C. Lurquin, E. De Plaen, F. Brasseur, D. Rimoldi, and T. Boon. 1999. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int. J. Cancer 83: 664-669. (Pubitemid 29508047)
7. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679.
8. Schmitz, M., P. Diestelkoetter, B. Weigle, F. Schmachtenberg, S. Stevanovic, D. Ockert, H. G. Rammensee, and E. P. Rieber. 2000. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60: 4845-4849.
9. Andersen, M. H., J. C. Becker, and P. Thor Straten. 2005. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 19: 484-485.
10. Wang, X. F., J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillère. 2008. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 181: 431-439.
11. Kadomatsu, K., M. Tomomura, and T. Muramatsu. 1988. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem. Biophys. Res. Commun. 151: 1312-1318.
12. O'Brien, T., D. Cranston, S. Fuggle, R. Bicknell, and A. L. Harris. 1996. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res. 56: 2515-2518.
13. Ye, C., M. Qi, Q. W. Fan, K. Ito, S. Akiyama, Y. Kasai, M. Matsuyama, T. Muramatsu, and K. Kadomatsu. 1999. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br. J. Cancer 79: 179-184. (Pubitemid 28566945)
14. Koide, N., H. Hada, T. Shinji, K. Ujike, S. Hirasaki, Y. Yumoto, T. Hanafusa, K. Kadomatsu, H. Muramatsu, T. Muramatsu, and T. Tsuji. 1999. Expression of the midkine gene in human hepatocellular carcinomas. Hepatogastroenterology 46: 3189-3196.
15. Haynes, L., and M. Rumsby. 2001. The pleiotropin/midkine family of cytokines: role in glial-neuronal signalling. Prog. Brain Res. 132: 313-324.
16. Sato, W., K. Kadomatsu, Y. Yuzawa, H. Muramatsu, N. Hotta, S. Matsuo, and T. Muramatsu. 2001. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J. Immunol. 167: 3463-3469. (Pubitemid 32852592)
17. Maruyama, K., H. Muramatsu, N. Ishiguro, and T. Muramatsu. 2004. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 50: 1420-1429. (Pubitemid 38608063)
18. Choudhuri, R., H. T. Zhang, S. Donnini, M. Ziche, and R. Bicknell. 1997. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 57: 1814-1819. (Pubitemid 27199678)
19. Muramatsu, H., and T. Muramatsu. 1991. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem. Biophys. Res. Commun. 177: 652-658.
20. Wang, Q., Y. Huang, Y. Ni, H.Wang, and Y. Hou. 2007. siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization. J. Biomed. Sci. 14: 783-795.
21. Takei, Y., K. Kadomatsu, S. Matsuo, H. Itoh, K. Nakazawa, S. Kubota, and T. Muramatsu. 2001. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res. 61: 8486-8491. (Pubitemid 33131129)
22. Maeda, S., H. Shinchi, H. Kurahara, Y. Mataki, H. Noma, K. Maemura, K. Aridome, T. Yokomine, S. Natsugoe, T. Aikou, and S. Takao. 2007. Clinical significance of midkine expression in pancreatic head carcinoma. Br. J. Cancer 97: 405-411. (Pubitemid 47196750)
23. Ikematsu, S., A. Nakagawara, Y. Nakamura, M. Ohira, M. Shinjo, S. Kishida, and K. Kadomatsu. 2008. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci. 99: 2070-2074.
24. Kaifi, J. T., H. C. Fiegel, S. L. Rafnsdottir, K. Aridome, P. G. Schurr, U. Reichelt, R. Wachowiak, H. Kleinhans, E. F. Yekebas, O. Mann, et al. 2007. Midkine as a prognostic marker for gastrointestinal stromal tumors. J. Cancer Res. Clin. Oncol. 133: 431-435.
25. Ikematsu, S., K. Okamoto, Y. Yoshida, M. Oda, H. Sugano-Nagano, K. Ashida, H. Kumai, K. Kadomatsu, H. Muramatsu, Takashi Muramatsu, and S. Sakuma. 2003. High levels of urinary midkine in various cancer patients. Biochem. Biophys. Res. Commun. 306: 329-332.
26. Neri, S., E. Mariani, A. Meneghetti, L. Cattini, and A. Facchini. 2001. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn. Lab. Immunol. 8: 1131-1135.
27. Firat, H., F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, Z. Garcia, M. L. Michel, R. W. Jack, G. Jung, K. Kosmatopoulos, et al. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29: 3112-3121.
28. Kadomatsu, K., and T. Muramatsu. 2004. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204: 127-143. (Pubitemid 38167717)
29. Maehara, H., T. Kaname, K. Yanagi, H. Hanzawa, I. Owan, T. Kinjou, K. Kadomatsu, S. Ikematsu, T. Iwamasa, F. Kanaya, and K. Naritomi. 2007. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem. Biophys. Res. Commun. 358: 757-762.
30. Miyauchi, M., Y. Yoshida, Y. Tada, M. Narita, T. Maeda, R. Bahar, K. Kadomatsu, T. Muramatsu, S. Matsubara, A. Nakagawara, et al. 2001. Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int. J. Cancer 91: 723-727.
31. Zou, P., H. Muramatsu, M. Sone, H. Hayashi, T. Nakashima, and T. Muramatsu. 2006. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. Lab. Invest. 86: 645-653.
32. Slager, E. H., M. W. Honders, E. D. van der Meijden, S. A. van Luxemburg- Heijs, F. M. Kloosterboer, M. G. Kester, I. Jedema, W. A. Marijt, M. R. Schaafsma, R. Willemze, and J. H. Falkenburg. 2006. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 107: 4954-4960.
33. Correale, P., K. Walmsley, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang. 1998. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. 161: 3186-3194.
34. Godefroy, E., A. Moreau-Aubry, E. Diez, B. Dreno, F. Jotereau, and Y. Guilloux. 2005. alpha v beta3-dependent cross-presentation of matrix metalloproteinase- 2 by melanoma cells gives rise to a new tumor antigen. J. Exp. Med. 202: 61-72.
35. El Hage, F., V. Stroobant, I. Vergnon, J. F. Baurain, H. Echchakir, V. Lazar, S. Chouaib, P. G. Coulie, and F. Mami-Chouaib. 2008. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc. Natl. Acad. Sci. USA 105: 10119-10124.
36. Yokoyama, Y., F. Grünebach, S. M. Schmidt, A. Heine, M. Häntschel, S. Stevanovic, H. G. Rammensee, and P. Brossart. 2008. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin. Cancer Res. 14: 5503-5511.
37. Shaffer, K. L., A. Sharma, E. L. Snapp, and R. S. Hegde. 2005. Regulation of protein compartmentalization expands the diversity of protein function. Dev. Cell 9: 545-554.
38. Lilley, B. N., and H. L. Ploegh. 2004. A membrane protein required for dislocation of misfolded proteins from the ER. Nature 429: 834-840.
39. Suzuki, N., Y. Shibata, T. Urano, T. Murohara, T. Muramatsu, and K. Kadomatsu. 2004. Proteasomal degradation of the nuclear targeting growth factor midkine. J. Biol. Chem. 279: 17785-17791.
40. Hegde, R. S., and H. D. Bernstein. 2006. The surprising complexity of signal sequences. Trends Biochem. Sci. 31: 563-571.
41. Rammensee, H. G., T. Friede, and S. Stevanoviíc. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
42. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443-446.
43. Guéguen, M., W. E. Biddison, and E. O. Long. 1994. T cell recognition of an HLA-A2-restricted epitope derived from a cleaved signal sequence. J. Exp. Med. 180: 1989-1994.
44. Wölfel, C., I. Drexler, A. Van Pel, T. Thres, N. Leister, W. Herr, G. Sutter, C. Huber, and T. Wölfel. 2000. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. Int. J. Cancer 88: 432-438.
45. Mitchell, M. S., T. A. Lund, A. K. Sewell, F. M. Marincola, E. Paul, K. Schroder, D. B. Wilson, and J. Kan-Mitchell. 2007. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2. Cancer Immunol. Immunother. 56: 287-301.
46. Konishi, N., M. Nakamura, S. Nakaoka, Y. Hiasa, M. Cho, H. Uemura, Y. Hirao, T. Muramatsu, and K. Kadomatsu. 1999. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 57: 253-257. (Pubitemid 29481700)
47. Muramatsu, H., X. J. Song, N. Koide, H. Hada, T. Tsuji, K. Kadomatsu, T. Inui, T. Kimura, S. Sakakibara, and T. Muramatsu. 1996. Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J. Biochem. 119: 1171-1175.
48. Ikematsu, S., A. Yano, K. Aridome, M. Kikuchi, H. Kumai, H. Nagano, K. Okamoto, M. Oda, S. Sakuma, T. Aikou, et al. 2000. Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer 83: 701-706.
49. Shimada, H., Y. Nabeya, M. Tagawa, S. Okazumi, H. Matsubara, K. Kadomatsu, T. Muramatsu, S. Ikematsu, S. Sakuma, and T. Ochiai. 2003. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 94: 628-632. (Pubitemid 36975019)
50. Obata, Y., S. Kikuchi, Y. Lin, K. Yagyu, T. Muramatsu, H. Kumai, and Tokyo Research Group on Prevention of Gastric Cancer. 2005. Serum midkine concentrations and gastric cancer. Cancer Sci. 96: 54-56.
51. Loirat, D., M. Mancini-Bourgine, J. P. Abastado, and M. L. Michel. 2003. HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int. Immunol. 15: 1125-1136.